BMEA (Biomea Fusion, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BMEA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Elizabeth Faust | Director | A | — | — |
| 2026-06-12 | Julianne Averill | Director | A | — | — |
| 2026-06-12 | Sumita Ray | Director | A | — | — |
| 2026-06-12 | ERIC AGUIAR | Director | A | — | — |
| 2026-04-03 | Rainer M Erdtmann | See Remarks | A | — | — |
| 2026-04-03 | Michael J.M. Hitchcock | Interim CEO | A | — | — |
| 2025-12-15 | Rainer M Erdtmann | See Remarks | Buy | — | — |
| 2025-12-04 | Michael J.M. Hitchcock | Interim CEO | Buy | — | — |
| 2025-12-02 | Rainer M Erdtmann | See Remarks | Buy | — | — |
| 2025-08-13 | Michael J.M. Hitchcock | Interim CEO | A | — | — |
| 2025-08-13 | Rainer M Erdtmann | See Remarks | G | — | — |
| 2025-08-01 | Cormorant Global Healthcare Master Fund, LP | — | — | — | — |
| 2025-07-24 | Julianne Averill | Director | A | — | — |
| 2025-06-13 | Elizabeth Faust | Director | A | — | — |
| 2025-06-13 | Sumita Ray | Director | A | — | — |
| 2025-06-13 | ERIC AGUIAR | Director | A | — | — |
| 2025-06-13 | Cormorant Private Healthcare Fund III LP | 10%+ Owner | A | — | — |
| 2025-03-28 | Michael J.M. Hitchcock | Interim CEO | A | — | — |
| 2024-12-02 | Franco Valle | Chief Financial Officer | A | — | — |
| 2024-10-01 | Michael J.M. Hitchcock | Director | Buy | — | — |
| 2024-06-13 | ERIC AGUIAR | Director | A | — | — |
| 2024-06-13 | Michael J.M. Hitchcock | Director | A | — | — |
| 2024-06-13 | Sumita Ray | Director | A | — | — |
| 2024-06-13 | Elizabeth Faust | Director | A | — | — |
| 2024-06-13 | Cormorant Global Healthcare Master Fund, LP | 10%+ Owner | A | — | — |
| 2024-06-12 | Juan Pablo Frias | Chief Medical Officer | A | — | — |
| 2024-06-12 | Franco Valle | Chief Financial Officer | MIXED | — | — |
| 2024-01-18 | Juan Pablo Frias | Chief Medical Officer | A | — | — |
| 2024-01-18 | Thomas Andrew Butler | Chief Executive Officer | A | — | — |
| 2024-01-18 | Franco Valle | Chief Financial Officer | A | — | — |
| 2024-01-18 | Rainer M Erdtmann | President and COO | A | — | — |
| 2024-01-03 | Rainer M Erdtmann | President and COO | G | — | — |
| 2023-12-01 | Franco Valle | Chief Financial Officer | A | — | — |
| 2023-09-01 | Juan Pablo Frias | Chief Medical Officer | A | — | — |
| 2023-06-16 | ERIC AGUIAR | Director | A | — | — |
| 2023-06-16 | Elizabeth Faust | Director | A | — | — |
| 2023-06-16 | Sumita Ray | Director | A | — | — |
| 2023-06-16 | Michael J.M. Hitchcock | Director | A | — | — |
| 2023-06-16 | Bihua Chen | Director | A | — | — |
| 2023-06-02 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | — | — |
| 2023-06-02 | Franco Valle | Chief Financial Officer | A | — | — |
| 2023-05-17 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | — | — |
| 2023-05-10 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | — | — |
| 2023-04-26 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | — | — |
| 2023-04-06 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | — | — |
| 2023-04-06 | A2A Pharmaceuticals, Inc. | 10%+ Owner | Sell | — | — |
| 2023-04-03 | Cormorant Global Healthcare Master Fund, LP | 10%+ Owner | Buy | — | — |
| 2023-02-10 | Rainer M Erdtmann | President and COO | Buy | — | — |
| 2023-01-10 | Rainer M Erdtmann | President and COO | A | — | — |
| 2023-01-10 | Thomas Andrew Butler | Chief Executive Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,400,000 | — |
| — | Director | 3,570,872 | — |
| — | 10%+ Owner | 3,570,872 | — |
| — | 10%+ Owner | 3,570,872 | — |
| — | 10%+ Owner | 3,550,000 | — |
| — | Director | 3,170,872 | — |
| — | See Remarks | 1,858,016 | — |
| — | Chief Executive Officer | 539,206 | — |
| — | Interim CEO | 115,000 | — |
| — | Chief Financial Officer | 42,995 | — |
| — | Chief Medical Officer | 349 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BMEA quote page; the site-wide leaderboard is on the insider transactions hub.